Mutations in ATF1 Gene Lead To Neuronal Damage and Neurodegenerative Diseases

Target Name: ATF1

NCBI ID: G466

ATF1

Mutations in ATF1 Gene Lead To Neuronal Damage and Neurodegenerative Diseases

The Ataxia-Telencephalopathy (ATF1) gene, also known as FUS/ATF-1, is a gene that encodes a protein known as ubiquitinase B (p-complex). Mutations in this gene lead to the loss of ATF1 protein, leading to neuronal damage and neurodegenerative diseases. At the same time, research also shows that ATF1 gene knockout can also lead to neuronal damage and neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

The relationship between ATF1 gene mutations and neuronal damage has been confirmed in multiple experiments and studies. For example, scientists have observed neuronal damage and the occurrence of neurodegenerative diseases, such as neuronal apoptosis and synapse loss, in ATF1 knockout rats. In addition, researchers also found that ATF1 gene knockout can lead to excessive activation of neurons, leading to neuronal damage.

In addition to neuronal damage, knockout of the ATF1 gene can lead to the occurrence of other neurodegenerative diseases. For example, studies have shown that knockout of the ATF1 gene leads to an increased incidence of Parkinson's disease, a common neurodegenerative disease that often causes muscle rigidity and movement disorders. In addition, ATF1 gene knockout can lead to Alzheimer's disease and other neurodegenerative diseases, which can also lead to neuronal damage and death.

In addition, studies have also shown that knockout of the ATF1 gene is related to the occurrence of other neurodegenerative diseases. For example, studies have shown that ATF1 gene knockout is associated with neuronal apoptosis and neuronal damage, and these processes are closely related to the occurrence and development of neurodegenerative diseases.

Knockout of the ATF1 gene also affects the occurrence of other neurodegenerative diseases. For example, studies have shown that ATF1 gene knockout is associated with the development of Parkinson's disease and Alzheimer's disease. these diseases

Protein Name: Activating Transcription Factor 1

Functions: This protein binds the cAMP response element (CRE) (consensus: 5'-GTGACGT[AC][AG]-3'), a sequence present in many viral and cellular promoters. Binds to the Tax-responsive element (TRE) of HTLV-I. Mediates PKA-induced stimulation of CRE-reporter genes. Represses the expression of FTH1 and other antioxidant detoxification genes. Triggers cell proliferation and transformation

The "ATF1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ATF1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets